Rate Video

ESMO WCGIC 2020 | SWOG S1310: trametinib vs 5-FU/capecitabine in refractory advanced biliary cancer

Richard D. Kim • 2 Jul 2020

ESMO WCGIC 2020

Bile Duct Cancer Gastrointestinal Cancer 5-fluorouracil Antibodies Capecitabine Trametinib

Richard Kim, MD, Moffitt Cancer Center, Tampa, FL, outlines results from a Phase II trial evaluating single agent MEK inhibitor trametinib versus 5-fluorouracil (5-FU) or capecitabine in refractory advanced biliary cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Adding chemotherapy to immunotherapy in metastatic CRC

Richard D. Kim • 6 Jun 2022

Nivolumab for CCA

Biomarker analysis of nivolumab in patients with advanced refractory biliary tract cancer

Richard D. Kim • 26 Jan 2023

Biomarkers of treatment response in patients with MMR-proficient CRC

Richard D. Kim • 26 Jan 2023

Related Videos

Regorafenib in refractory biliary tract cancer

COVID-19 & the management of cancer patients

Alberto F. Sobrero

HER-2 conversion: a phenomenon in trastuzumab resistance

The gut microbiome: role in causing and detecting colorectal cancer